Join to access to all OVN content. Join for Free

Results for 'CVD'

Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials
OVN Avatar Janice Bonsu, MPH, Lawrence Charles, MD, Avirup Guha, MD, Farrukh Awan, MD, MS, Jennifer Woyach, MD, Vedat Yildiz, MS, Lai Wei, PhD, Hani Jneid, MD, and Daniel Addison, MD
Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials

cancer, cardiovascular disease, clinical trials, underrepresentation, United States Food and Drug Administration, FDA, CVD

Heart failure (28%) was the most common exclusion criterion in clinical trials for FDA-approved anticancer therapies, followed by prior coronary disease and arrhythmias (27% and 23%, respectively). Over one-third of trials excluded patients with underlying cardiovascular disease (CVD), including mor…

Mar 18th • 3 mins read

Related Topics

Loading...